Richard Pulik's most recent trade in Roivant Sciences Ltd was a trade of 1,919 Common Shares done at an average price of $11.4 . Disclosure was reported to the exchange on July 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.35 per share. | 28 Jul 2025 | 1,919 | 397,553 | - | 11.4 | 21,781 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.39 per share. | 28 Jun 2025 | 1,653 | 399,472 | - | 11.4 | 18,828 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.45 per share. | 20 Jun 2025 | 1,503 | 399,056 | - | 11.4 | 17,209 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.62 per share. | 28 May 2025 | 1,653 | 400,559 | - | 10.6 | 17,555 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.04 per share. | 20 May 2025 | 3,487 | 402,212 | - | 11.0 | 38,496 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share. | 28 Apr 2025 | 1,653 | 405,699 | - | 11.2 | 18,497 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2025 | 180,413 | 180,413 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Richard Pulik | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2025 | 141,464 | 407,352 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.38 per share. | 28 Mar 2025 | 1,653 | 265,888 | - | 10.4 | 17,158 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. | 20 Mar 2025 | 1,504 | 267,541 | - | 11.0 | 16,499 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.74 per share. | 28 Feb 2025 | 1,635 | 269,045 | - | 10.7 | 17,560 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.15 per share. | 28 Jan 2025 | 1,896 | 270,680 | - | 11.1 | 21,140 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.80 per share. | 28 Dec 2024 | 1,896 | 272,576 | - | 11.8 | 22,373 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.57 per share. | 20 Dec 2024 | 2,129 | 274,472 | - | 11.6 | 24,633 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. | 28 Nov 2024 | 2,341 | 276,601 | - | 12.7 | 29,707 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.84 per share. | 28 Oct 2024 | 2,341 | 278,942 | - | 11.8 | 27,717 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.48 per share. | 28 Sep 2024 | 2,340 | 281,283 | - | 11.5 | 26,863 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.97 per share. | 20 Sep 2024 | 2,129 | 283,623 | - | 12.0 | 25,484 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.00 per share. | 28 Aug 2024 | 2,341 | 285,752 | - | 12 | 28,092 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.80 per share. | 28 Jul 2024 | 2,341 | 288,093 | - | 10.8 | 25,283 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.57 per share. | 28 Jun 2024 | 2,340 | 290,434 | - | 10.6 | 24,734 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.80 per share. | 20 Jun 2024 | 2,129 | 290,572 | - | 10.8 | 22,993 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.83 per share. | 28 May 2024 | 2,341 | 292,701 | - | 10.8 | 25,353 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.03 per share. | 28 Apr 2024 | 2,340 | 295,042 | - | 11.0 | 25,810 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2024 | 302,594 | 302,594 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Richard Pulik | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2024 | 38,685 | 297,382 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.46 per share. | 20 Apr 2024 | 8,515 | 258,697 | - | 10.5 | 89,067 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.54 per share. | 28 Mar 2024 | 2,341 | 267,212 | - | 10.5 | 24,674 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.71 per share. | 28 Feb 2024 | 1,630 | 269,553 | - | 11.7 | 19,087 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.37 per share. | 28 Jan 2024 | 1,896 | 271,183 | - | 10.4 | 19,662 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.37 per share. | 28 Dec 2023 | 1,913 | 273,079 | - | 11.4 | 21,751 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Other type of transaction at price $ 11.19 per share. | 29 Aug 2023 | 2,368 | 282,195 | - | 11.2 | 26,498 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Other type of transaction at price $ 11.86 per share. | 01 Aug 2023 | 2,306 | 284,563 | - | 11.9 | 27,349 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Other type of transaction at price $ 10.11 per share. | 29 Jun 2023 | 1,667 | 283,373 | - | 10.1 | 16,853 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Other type of transaction at price $ 8.61 per share. | 01 May 2023 | 1,667 | 286,751 | - | 8.6 | 14,353 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2023 | 383,496 | 383,496 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Richard Pulik | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2023 | 66,710 | 288,418 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Richard Pulik | CFO | Other type of transaction at price $ 7.35 per share. | 29 Mar 2023 | 1,639 | 221,708 | - | 7.4 | 12,047 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CFO | Sale of securities on an exchange or to another person at price $ 8.08 per share. | 01 Mar 2023 | 1,912 | 223,347 | - | 8.1 | 15,449 | Common Shares |
| Roivant Sciences Ltd | Richard Pulik | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2021 | 313,419 | 313,419 | - | - | Stock Option (Right to Buy) |